NCT06479187
PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer
StatusActive, Not Recruiting
PhasePhase 4
SponsorBrigham and Women's Hospital
Primary completion (estimated)
At risk: Primary completion moved 6 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Jun 30, 2026 to Dec 30, 2026
- Eligibility criteria expanded, about 15 words
- Interventions: 18F-rhPSMA-7.3 (Drug), PET/CT (Device) to 18F-rhPSMA-7.3 (Drug), PET/CT (Device)
- Study description expanded, about 4 words
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 2 of 2 sites
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 1 to 2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Proportion of patients with residual PSMA-avid disease on 18F-rhPSMA7.3 PSMA PET after 6 months of treatment for metastatic hormone sensitive prostate cancer
Timeframe: At the time of the 18F-rhPSMA-7.3 PSMA-PET/CT scan done 6 months after starting therapy for metastatic hormone sensitive prostate cancer
Arms and interventions
PSMA-PET/CT armExperimental
Patients will undergo 18F-rhPSMA-7.3 PSMA PET/CT scan before and after 6 months of treatment for metastatic hormone sensitive prostate cancer. Patients will undergo chart review every 3 months for 1 year after the second 18F-rhPSMA-7.3 PSMA PET/CT scan.
Drugs: 18F-rhPSMA-7.3
Devices: PET/CT
Sites
2 sites in 1 country